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Abstract
Lysine acetylation has emerged as a dominant post-translational modification (PTM) regu-
lating tau proteins in Alzheimer’s disease (AD) and related tauopathies. Mass spectrometry
studies indicate that tau acetylation sites cluster within the microtubule-binding region
(MTBR), a region that is highly conserved among tau, MAP2, and MAP4 family members,
implying that acetylation could represent a conserved regulatory mechanism for MAPs
beyond tau. Here, we combined mass spectrometry, biochemical assays, and cell-based
approaches to demonstrate that the tau family members MAP2 and MAP4 are also subject
to reversible acetylation. We identify a cluster of lysines in the MAP2 and MAP4 MTBR that
undergo CBP-catalyzed acetylation, many of which are conserved in tau. Similar to tau,
MAP2 acetylation can occur in a cysteine-dependent auto-regulatory manner in the pres-
ence of acetyl-CoA. Furthermore, tubulin reduced MAP2 acetylation, suggesting tubulin
binding dictates MAP acetylation status. Taken together, these results uncover a striking
conservation of MAP2/Tau family post-translational modifications that could expand our
understanding of the dynamic mechanisms regulating microtubules.
Introduction
The microtubule (MT)-associated protein (MAP) tau is expressed primarily in the nervous
system, in which six tau isoforms exist containing either three (3R-tau) or four (4R-tau) MT-
binding repeat domains. Along with the flanking regions, the MT-binding domains coordinate
tau-MT binding and stabilization [1, 2]. Over the last several years, we and others demon-
strated that tau is subject to lysine acetylation mainly within the MT-binding repeat region
(MTBR), identifying a new and emerging post-translational modification (PTM) that could
dominantly regulate multiple aspects of tau function [3–7]. Indeed, our previous in vitro
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experiments showed that tau acetylation is sufficient to impair normal tau-MT interactions,
prevent tau-mediated stabilization of MTs, and promote the formation of tau fibrils that
resemble those observed in diseased brain [3].
Neuropathological analysis of human brain tissue showed that acetylated tau at residue
K280 (Lys280) within the tau MTBR accumulated in tauopathy brains and produced a dis-
tinctly pathological signature in Alzheimer’s disease (AD) and also a panel of other tauopathies
including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and several
FTDP-17 familial dementia patients. K280-acetylated tau was not readily detectable in control
brain tissue or cultured wild-type cells or neurons, thus correlating tau acetylation at K280
with the onset or progression of tauopathy [8, 9]. Recently, however, more sensitive mass spec-
trometry studies indicated that tau is normally acetylated in wild-type mouse brain at several
lysines spanning the MTBR, suggesting a normal physiological role for tau acetylation in regu-
lating MT-binding or MT stabilization [7]. Supporting this possibility, early biochemical stud-
ies showed that positively charged tau residues K280 and K281 directly contact MTs, strongly
implicating this double lysine containing PHF6 motif (275VQIINK/K281) as a critical hotspot
for tau-MT binding in addition to facilitating conformational β-structure and tau aggregation
[10]. Either genetic deletion of residue K280 (ΔK280), as observed in familial FTDP-17 demen-
tia [11], or lysine acetylation on residue K280, as observed in AD and related tauopathies [3],
may be sufficient to neutralize the positive charge within this region, thereby impairing tau-
MT interactions. The homologous lysine residue residing in the 3rd MTBR repeat, K311 within
the PHF6 motif (306VQIVYK311), has also been shown to regulate tau biochemical properties,
as a variety of substitutions at residue K311 alter tau aggregation kinetics [12]. Thus, MTBR
lysines likely engage in critical electrostatic charge interactions; these are the same lysine resi-
dues that are also subject to acetylation, which functionally regulates tau-MT binding and sta-
bilizing activity. Whether acetylation-dependent mechanisms similarly regulate MAPs beyond
tau has not been investigated.
The abundance of tau acetylation sites in normal wild-type mice supports a broader physio-
logical role for MAP acetylation in cytoskeletal dynamics [7]. Tau is highly homologous to the
related MAP2 and MAP4 proteins [13, 14], which possess 3 or 4 MTBRs with highly conserved
lysine-rich repeats. While global MAP acetylation per se has not been characterized, evidence
supports an emerging network of acetylated factors localized to the cytoskeleton and also asso-
ciated with MTs [15]. Moreover, components of the acetylation machinery are particularly
enriched in close proximity to MTs including acetyltransferases such as the Elongator complex
[16] and tubulin acetyltransferse (TAT) [17] as well as the deacetylases HDAC6 [18] and
SIRT2 [19]. In this study, we describe lysine acetylation as a novel conserved regulatory mech-
anism among MAP2/Tau family members, which has implications for the regulation of MAP
function and microtubule dynamics.
Materials and Methods
Plasmids and Cell Culture
The human tau isoform containing 2 N-terminal inserts and 4 MTBR regions (2N4R) was
cloned into pCDNA5/TO vector (Invitrogen). A rat MAP2c construct containing an HA-tag
was kindly provided by Dr. Shelley Halpain (University of California, San Diego) and a human
MAP4-GFP plasmid was kindly provided by Dr. Chloe Bulinski (Columbia University). A
plasmid containing wild-type CBP or the inactive L1435A/D1436A mutant (pcDNA3.1-CBP
and CBP-LD) was kindly provided by Dr. Tso-Pang Yao (Duke University). All described plas-
mids were transfected into QBI-293 cells using Fugene-6 (Promega) or Lipofectamine 2000
(Thermofisher) reagents per the manufacturers protocols. Transfected QBI-293 cells were
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evaluated for MT bundling by immunofluorescence microscopy using anti-tau/MAP2 anti-
bodies (polyclonal anti-tau, Dako), anti-MAP4-GFP (polyclonal anti-GFP, Santa Cruz), and
anti-acetylated tubulin antibodies (Sigma).
Recombinant in vitro methods
Purified MAP protein preparations. Tau-K18 (2N4R-tau spanning residues 244–372),
MAP2c fragments (spanning residues 280–398 of the full-length 467 residue rat MAP2c), and
MAP4 fragments (spanning residues 925–1102 of full-length 1152 residue human MAP4)
were purified using an AKTA-Pure FPLC chromatography system (GE). The proteins were
expressed in Escherichia coli BL21(DE3) RIL strain. Bacteria were grown in LB media contain-
ing ampicillin at 37˚C and induced with isopropyl-D -thiogalactopyranoside at a final concen-
tration of 0.8 mM when the OD reached 0.6. After agitation for 2 h, cells were harvested by
centrifugation. The pellet was re-suspended in high-salt RAB buffer [0.1 M MES, 1 mM
EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 0.1 mM PMSF, 0.1% protease inhibitor
cocktail (100 μg/mL each of pepstatin A, leupeptin, TPCK, TLCK, and soybean trypsin inhibi-
tor and 100 mM EDTA), pH 7.0] and homogenized. The cell lysates were heated to 100˚C for
10 min, rapidly cooled on ice for 20 min and centrifuged at 70,000xg for 30 min. Supernatants
were dialyzed into FPLC buffer A [20 mM piperazine-N, N-bis(2-ethanesulfonic acid) pH 6.5,
10 mM NaCl, 1 mM EGTA, 1 mM MgSO4, 2 mM DTT, 0.1 mM PMSF], applied onto a HiTrap
Sepharose HP IEX cation-exchange column (GE Healthcare), and eluted with a 0–0.4 M NaCl
gradient using an AKTA-Pure FPLC system (GE Healthcare). The fractions were checked for
the presence of the tau proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS- PAGE) followed by Coomassie Blue R-250 staining. The fractions containing enriched
tau or MAP2c were pooled together and dialyzed against 100 mM sodium acetate buffer, pH
7.0. Importantly, all purified proteins were subject to a critical heat-denaturation step at 100˚C
to inactivate any endogenous bacterial enzymes and simultaneously enrich for heat-stable tau
proteins. Proteins were concentrated using Amicon Ultra centrifugal filter units (Millipore
Corporation, Billerica, MA), and protein concentrations were determined using the bicincho-
ninic acid protein assay (Pierce, Rockford, IL) with bovine serum albumin as the protein
standard.
In vitro acetylation reactions. Tau, MAP2c, or MAP4 fragments (5 μM) were either
mock acetylated with coenzyme A alone or modified in vitro using acetyl-CoA (Sigma) in acet-
ylation reaction buffer (50 mM Tris–HCl pH 8.0, 10% glycerol, 1 mM DTT, 100 μM EDTA, 1
mM PMSF, 0.4 mM acetyl-CoA cofactor) at 37˚C for 1hr. For radiolabeling experiments, 50
nCi [14C]-labeled acetyl-CoA (Perkin Elmer) was substituted for unlabeled acetyl-CoA. Reac-
tion products were analyzed by resolving proteins on 15% SDS-PAGE gels followed by transfer
to nitrocellulose membranes and phosphorimaging analysis using Storm software, or immu-
noblotting with the indicated antibodies. MAP-rich fractions containing bovine brain-derived
MAPs were purchased from Cytoskeleton and desalted, where indicated, using Zeba Spin
Desalting Columns (Thermofisher) prior to acetylation reactions. For tubulin competition
experiments, purified brain tubulin (Cytoskeleton) was titrated into acetylation reactions at
final concentration of 1–10 μM and preincubated for 10 min at 37˚C prior to initiation of acet-
ylation by addition of acetyl-CoA. All reactions were performed with a minimum of N = 3
independent experimental replicates.
For filter-binding assays, reactions containing tau-K18, MAP2c, or MAP4 fragments were
initiated by the addition of [3H]-acetyl-CoA (2.35 Ci mmol-1, Perkin Elmer) at concentrations
ranging from 2.5 μM to 1 mM acetyl-CoA, incubated at 37˚ C, and allowed to proceed for 1 hr.
Reactions were stopped by the addition of 10 μl of 3 mM CoA, and 25 μl of the reaction was
MAP2/Tau Family Members Undergo Lysine Acetylation
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then spotted to a P81 filter paper (Whatman), washed in 10 mM HEPES pH 7.5 three times,
and dried using acetone. Incorporated [3H]-acetyl-CoA was then measured using the Perkin
Elmer Tri-Carb 2800TR Liquid Scintillation Analyzer, and the molar amount of acetyl groups
incorporated were calculated from a standard curve of the radiolabeled acetyl-CoA.
Biochemical analysis of mouse brain
This study was carried out in accordance with the University of North Carolina (UNC) Institu-
tional Animal Care and Use Committee (IACUC). The protocol was approved by the UNC
IACUC Committee (ID# Number: 14.107.0). Mice were anesthetized with isoflurane or a keta-
mine/xylazine mixture and all efforts were made to minimize pain suffering. Whole cortex
from wild-type (WT) and tau knock-out (KO) mice were high-salt extracted, boiled where
indicated, and resulting homogenates were incubated with acetyl-CoA containing reaction
buffers. For acetyltransferase assays using brain lysates, boiled mouse lysates or salt-extracted
human lysates were dialyzed into PBS and supplemented with Tris pH 8.0 to a final concentra-
tion of 50 mM.
Biochemical extraction of cultured cells
Cells from 6-well culture dishes were scraped into 300 μl RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) containing
1 mM phenylmethylsulfonyl fluoride (PMSF), a mixture of protease inhibitors (1 μM pepsta-
tin, leupeptin, N-p-Tosyl-l-phenylalanine chloromethyl ketone, Nα-Tosyl-l-lysine chloromethyl
ketone hydrochloride, trypsin inhibitor; Sigma), and a mixture of phosphatase inhibitors (2 mM
imidazole, 1 mM NaF, 1 mM sodium orthovanadate; Sigma). Cell homogenates were sonicated
and centrifuged at 100,000xg for 30 min at 4˚C to provide a RIPA soluble fraction. Soluble lysates
were analyzed by immunoblotting using the described antibodies. The antibodies used for west-
ern analysis were as follows: polyclonal anti-acetylated-lysine (1:1000, Cell Signaling #9441),
anti-tau C-terminal clone T46 (1:1000, Thermofisher), and anti-acetylated tau, Ac-K280 [3]
(1:1000), polyclonal anti-GFP (1:1000, Santa Cruz).
Cell-based immunoprecipitation/acetylation reactions
Acetyltransferase assays were performed by immunoprecipitating tau or MAP2c proteins
(using anti-tau/MAP2 antibody, clone T46) (Thermofisher) or MAP4 (using polyclonal anti-
GFP) (Santa Cruz). MAPs were bound by protein A/G beads followed by immunoblotting
using polyclonal anti-acetyl-lysine antibodies (Cell Signaling) or alternatively radiolabeling
was performed by addition of [14C]-Acetyl-CoA (Perkin Elmer) for 2 hr at 37˚C. Radiolabeled
acetylated MAPs bound to beads were eluted and analyzed by SDS-PAGE and Coomassie
staining followed by phosphorimaging using Storm software. For acetyltransferase analysis
using WT and tau KO brain lysates, boiled high-salt extracted mouse cortical lysates were dia-
lyzed into PBS and supplemented to a final concentration of 50 mM Tris pH 8.0. The desired
cofactors, either CoA or acetyl-CoA, were supplemented to 1 mM and incubated for 2 hr at
37˚C followed by immunoblotting using the indicated antibodies.
Mass spectrometry
NanoLC nanospray MS-MS analysis was performed at the University of Pennsylvania proteo-
mics core facility, which identified acetylated MAP2c and MAP4 lysine residues (Tables 1 and
2). MAP proteins were immunoprecipitated with T46 (MAP2c) or GFP (MAP4) antibodies
and separated by SDS-PAGE followed by gel excision and mass spectrometry analysis using
MAP2/Tau Family Members Undergo Lysine Acetylation
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LTQ XL Linear Ion Trap Mass Spectrometer (Thermo Scientific). Data was acquired using
Xcalibur software (Thermo Scientific) and analyzed using Mascot, Scaffold, and/or PEAKS
software programs. Significantly acetylated peptide cutoffs showed p-values < 0.05 and pep-
tide scores > 20.
Results
MAP2/Tau family members are subject to lysine acetylation
In order to investigate MAP acetylation, we incubated mouse brain lysates (Fig 1A) or MAP-
rich fractions purified from bovine brain (Fig 1B) with acetyl-CoA in an in vitro acetylation
reaction. In both instances, we observed accumulation of acetylated target proteins ranging
from ~25–250 kDa even in the complete absence of tau proteins (~50–65 kDa) using tau KO
brain lysates, suggesting that MAPs in addition to tau are potentially subject to acetylation.
Furthermore, the ~250 kDa MAP2 band was strongly detected with the anti-acetyl-lysine
Table 1. Acetylated lysines identified in MAP2c
Site MTBR p-value Peptide
K107 N 9.40E-05 IVQVVTAEAVAVLKGEQEKEAQHK
K230 N 1.00E-07 AGKSGTSTPTTPGSTAITPGTPPSYSSR
K273 N 0.0025 TPGTPKSGILVPSEK
K273, K282 N 2.70E-05 TPGTPKSGILVPSEKK
K273, K283 N 3.90E-05 TPGTPKSGILVPSEKK
K282 N 0.024 SGILVPSEKK
K283 N 0.057 KVAIIR
K282, K283 N 2.60E-06 SGILVPSEKKVAIIR
K292 N 0.0065 TPPKSPATPK
K292, K298 N 0.068 TPPKSPATPKQLR
K298 N 0.022 SPATPKQLR
K311 Y 0.0013 LINQPLPDLKNVK
K314, K316 Y 0.00032 NVKSKIGSTDNIK
K316, K324 Y 5.40E-06 SKIGSTDNIKYQPK
K324 Y 0.00075 IGSTDNIKYQPK
K328 Y 0.00029 YQPKGGQVQIVTK
K328, K337 Y 6.20E-06 YQPKGGQVQIVTKK
K328, K338 Y 0.07 YQPKGGQVQIVTKK
K337 Y 5.00E-05 GGQVQIVTKK
K337, K338 Y 7.10E-07 GGQVQIVTKKIDLSHVTSK
K338 Y 3.60E-05 KIDLSHVTSK
K347 Y 0.0011 IDLSHVTSKCGSLK
K347, K352 Y 3.80E-05 IDLSHVTSKCGSLKNIR
K364, K369 Y 0.0092 VKIESVKLDFK
K369 Y 0.0024 VKIESVKLDFK
K379 Y 0.00055 AQAKVGSLDNAHHVPGGGNVK
K396 Y 2.50E-05 VGSLDNAHHVPGGGNVKIDSQK
K401 Y 7.90E-06 IDSQKLNFR
MAP2c acetylated lysines identified by mass spectrometry are listed by residue number using the 467 amino acid rat MAP2c sequence. The location of the
identified lysine within the MTBR (Yes/No), p-value for each peptide, and peptide sequence containing the primary acetylated lysine in bold are shown.
doi:10.1371/journal.pone.0168913.t001
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antibody in MAP-rich fractions incubated with acetyl-CoA and was more prominently
observed upon desalting of MAP fractions, which led to increased acetylation efficiency (Fig
1B).
To further evaluate MAP acetylation, we focused on MAP2c and MAP4. MAP2c is the
shortest MAP2 isoform that is amenable to molecular and biochemical analysis by virtue of its
lower molecular weight (~65–75 kDa) compared to the much larger full-length MAP2 isoform
(~250 kDa). Alignment of the MTBR domains of tau, MAP2c, and MAP4 highlights the exten-
sive ~75% homology within their functional repeats (Fig 2) [20]. All three MAPs possess highly
lysine-rich MTBRs that mediate MAP-MT electrostatic interactions, indicating the potential
for conserved acetylation within their repeats. Notably, tau/MAP4 alignments showed conser-
vation of critical tau residues K280/K281 within the 2nd repeat motif 275VQIINK/K281, and the
combined tau/MAP2c/MAP4 alignment showed conservation of the 3rd repeat motif harbor-
ing tau lysine K311, 306VQIVYK311 (Fig 2).
MAP2c and MAP4 acetylation was assessed by co-expression with the constitutively active
acetyltransferase CBP, previously shown to acetylate tau isoforms with high affinity using in
vitro and cell-based assays [3, 6, 21]. QBI-293 cells were employed for MAP acetylation experi-
ments since these cells have low levels of tau/MAP2 and are therefore amenable to MAP
expression studies without confounding levels of endogenous MAPs. MAP2c or MAP4 pro-
teins were immunoprecipitated from co-transfected cells, and MAP acetylation was detected
using an anti-acetyl-lysine antibody (Fig 3A). While MAP acetylation was undetectable in the
absence of CBP, co-expression with CBP led to the accumulation of acetylated MAP2c and
MAP4, which migrated as a series of acetylated protein bands ~ 65 kDa (MAP2c) and ~100
kDa (MAP4).
To identify acetylated lysine residues, large-scale transfections in the presence of CBP were
used to immunopurify acetylated MAP2c and MAP4 proteins, yielding highly purified MAPs,
as determined by Coomassie staining of eluted fractions. Approximately 5–10 μg of total puri-
fied MAPs were isolated from cell extracts (Fig 3B). Our MAP enrichment strategy enabled
highly sensitive detection of lysine acetylation by mass spectrometry analysis upon gel excision
Table 2. Acetylated lysines identified in MAP4
Site MTBR p-value peptide
K702 N 0.065 TKPLATTQPAK
K718 N 0.023 AKTQPTSLPK
K838, K847 N 0.0018 KPTAIKTEGKPAEVKK
K852 N 0.015 MTAKSVPADLSRPK
K871 N 0.00012 KTTTLSGTAPAAGVVPSR
K912 N 0.0074 KPTSAKPSSTTPR
K933 Y 0.0042 LATNTSAPDLKNVR
K938 Y 0.076 SKVGSTENIK
K997, K998 Y 0.05 VQIVSKKVSYSHIQSK
K1028 Y 0.019 HVPGGGNVQIQNKK
K1034 Y 0.00048 KVDISKVSSK
K1060 Y 0.002 IESQKLNFK
K1070 Y 0.031 AQAKVGSLDNVGHLPAGGAVK
MAP4 acetylated lysines identified by mass spectrometry are listed by residue number using the 1152 amino acid longest human MAP4 sequence. The
location of the identified lysine within the MTBR (Yes/No), p-value for each peptide, and peptide sequence containing the primary acetylated lysine in bold
are shown.
doi:10.1371/journal.pone.0168913.t002
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and subsequent acetylated peptide mapping using nanoLC/nanospray/MS/MS. We note that
incorporation of the deacetylase inhibitors trichostatin A (TSA) and nicotinamide (NCA),
which block HDAC/sirtuin family members, was critical to preserve MAP acetylation status
throughout the MAP extraction and isolation process.
Acetylated lysine-containing peptides were identified for both MAP2c (Table 1 and S1 Fig)
and MAP4 (Table 2), many of which clustered within the MTBR regions similar to tau proteins
(Fig 2). This observation was despite the fact that lysine residues are distributed throughout
MAP2c and MAP4, suggesting specificity for acetylation within the MTBR. We observed sev-
eral regions within the MTBRs of MAP2c and MAP4 that represent putative acetylation motifs
(Fig 2, see motifs highlighted by solid black lines). In repeat 1, we identified a conserved
lysine-rich cluster [K-N-V-K/R-S-K] in which either 2 or 3 lysines were acetylated in both
MAP2c and MAP4. Further acetylation site comparisons identified a more general consensus
motif [V-Q/K-I-X-X-X/K-K] present at the N-terminus of MAP2c repeats 3/4 and MAP4
repeats 2/3/4, in which several acetylated lysines were enriched. Consistent with these two
regions acting as putative MAP acetylation motifs, tau proteins are similarly acetylated in
repeat 1 at residue K259 [254K-N-V-K-S-K259] [4], repeat 2 at residues K280 and K281
Fig 1. MAP-rich fractions and mouse brain lysates contain targets of acetylation. A) Cortical brain tissue from wild-type (WT) and tau knock-out (KO)
mice were high-salt extracted, boiled where indicated, and resulting homogenates were incubated with acetyl-CoA containing reaction buffers. Samples
were analyzed by immunoblotting using anti-acetyl-lysine, Ac-K280, and total tau (T49) antibodies. B) MAP-rich fractions from bovine brain were desalted,
where indicated, and incubated with CoA or acetyl-CoA followed by immunoblotting similar to (A) above. Shown are representative immunoblot analysis
from N = 3 independent experiments.
doi:10.1371/journal.pone.0168913.g001
MAP2/Tau Family Members Undergo Lysine Acetylation
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[275V-Q-I-I-N-K-K281] [3, 22], and repeat 3 at residue K311 (306V-Q-I-V-Y-K311) [3]. Thus,
two distinct lysine-rich motifs within the MTBR emerged as conserved hot-spots that are par-
ticularly susceptible to acetylation, possibly due to distinct conformation and/or increased
lysine accessibility within these regions.
MAP acetylation can occur via an auto-catalytic mechanism
While previous studies have suggested that tau acetylation occurs in trans by CBP/p300 [3, 5,
6, 21], evidence also indicates that tau auto-acetylation occurs upon incubation of tau proteins
with acetyl-CoA alone [21]. Thus, to further confirm MAP acetylation and to determine if the
recently described tau auto-acetylation mechanism also applies to MAP2, a truncated MAP2c
fragment encompassing the MAP2 MTBR (residues 280–398) was generated and analyzed by
in vitro acetylation reactions with radiolabeled [14C]-acetyl-CoA. Tau and MAP2c acetylation
reactions were separated by SDS-PAGE gel, transferred to nitrocellulose membranes, and ana-
lyzed by autoradiography and phosphorimaging. In agreement with our previous study [21],
the tau-K18 fragment comprising the 4-repeat tau region (residues 244–372), showed robust
auto-acetylation, an effect that was similarly observed with the homologous MAP2c MTBR
fragment (Fig 4A).
To independently confirm MAP2c auto-acetylation, we isolated transfected tau or MAP2c
using immunoprecipitation pull-downs and performed auto-acetylation reactions on MAPs
bound to affinity beads, which showed that isolated full-length tau (2N4R) and MAP2c are
both capable of self-acetylation upon incubation with acetyl-CoA (Fig 4B). As a negative
Fig 2. Tau, MAP2c, and MAP4 sequence alignments illustrate extensive MTBR homology and conservation of critical lysines The
microtubule-binding repeats 1–4 from tau, MAP2c, and MAP4 were aligned and exact amino acid homology among the MAPs is depicted
with red shading. Solid black lines identify two putative MAP acetylation motifs (see Tables 1 and 2 for all identified acetylated residues), and
specific acetylated lysines that are enriched within the identified motifs are highlighted above the indicated lysine residues with filled black
circles.
doi:10.1371/journal.pone.0168913.g002
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control, a cysteine-less tau mutant (2N4R-2CA) that impairs auto-acetylation showed no
detectable radiolabeling [21]. Finally, direct incorporation of [3H]-acetyl groups onto MAP2c
and MAP4 lysine residues was measured by quantification of radiolabeled fragments using a
filter-binding assay that traps low-molecular weight MAP fragments but not free unconjugated
[3H]-acetyl-CoA. MAP2c and MAP4 fragments that span the MTBR showed significant acety-
lation, which increased linearly as a function of increasing concentration of acetyl-CoA from
2.5–800 μM (Fig 4C). The additional 2nd MTBR repeat present in MAP4, but not MAP2c, may
Fig 3. MAP2 and MAP4 are subject to reversible lysine acetylation A) QBI-293 cells were co-transfected with MAP2c or MAP4-GFP
expression plasmids in the presence of CBP to promote full acetylation, followed by immunoprecipitation and immunoblot analysis using
acetylated lysine, T46 or GFP antibodies. The monoclonal antibody T46 detects a highly conserved C-terminal epitope that is identical in tau
and MAP2c proteins. B) Immunoprecipitation reactions from cells transfected with vector alone (lane 1), MAP2c alone (lane 2), MAP2c and
CBP (lane 3), or MAP4 and CBP (lane 4) were performed with T46 or GFP antibodies. Samples were separated by SDS-PAGE and
Coomassie stained followed by gel band excision and analysis by mass spectrometry (NanoLC nanospray MS-MS, see methods). In the
absence of CBP, no lysine acetylation was detected. In the presence of CBP, MAP2c and MAP4 acetylation sites were identified and full
peptide details are listed in Tables 1 and 2. Shown are representative immunoblots from N = 3 independent experiments. Coomassie staining,
gel band excision, and mass spectrometry was performed in triplicate confirming the identity of acetylated lysine residues from three
independent MAP acetylation experiments.
doi:10.1371/journal.pone.0168913.g003
MAP2/Tau Family Members Undergo Lysine Acetylation
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account for the increased MAP4 acetylation observed at most acetyl-CoA concentrations.
Notably, mutation of the single MAP2c cysteine residue to an alanine (C348A) abrogated acet-
ylation, strongly supporting cysteine-mediated auto-acetylation [21]. Together, these data sug-
gest that CBP-catalyzed acetylation and chemical auto-acetylation are conserved among
MAP2/Tau family proteins.
MAP-Tubulin interactions are regulated by MAP acetylation
One primary function of MAPs is to bind and stabilize MTs [13], mediated partly via MTBR
lysines that associate with MTs [10]. The presence of tubulin is expected to engage MAP lysine
Fig 4. MAPs are subject to auto-acetylation within the MTBR domain A) Recombinant tau-K18 (residues 244–372) or MAP2c (residues 280–
388) fragments were incubated in acetylation reactions containing [14C]-labeled acetyl-CoA followed by SDS-PAGE and phosphorimaging using
Storm software to detect radiolabeled MAPs. B) Immunoprecipitated 2N4R tau (lane 1), 2N4R-2CA mutant tau (lane 2), or MAP2c proteins (lane 6)
derived from QBI-293 lysates were immobilized on agarose beads, incubated with [14C]-Acetyl-CoA, and analyzed by SDS-PAGE and Coomassie
staining followed by phosphorimaging analysis. Replicate IgG control samples (lanes 3–5) were used to clearly separate signal intensities from tau
and MAP2c sample lanes. C) Purified MTBR fragments from wild-type MAP2c (280–388), a comparable MAP2c fragment containing a
cysteine!alanine substitution (C348A), or MAP4 (925–1102) were incubated in acetylation reactions and direct incorporation of radiolabeled acetyl
groups was quantified using a liquid scintillation analyzer. Shown are representative analysis using N = 3 technical replicates from N = 3
independent experiments.
doi:10.1371/journal.pone.0168913.g004
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residues and therefore limit lysine accessibility required for acetyl group transfer. Thus, we
asked whether MAP acetylation still occurred in the presence of increasing concentrations of
tubulin. Purified MAP-rich brain fractions containing full-length MAP2 (250 kDa isoform)
were incubated with purified tubulin, which led to progressively reduced MAP2 acetylation
detected by [14C]-acetyl-CoA labeling (Fig 5A). Similarly, immunoblotting with anti-acety-
lated lysine antibodies showed reduced MAP2 acetylation and a simultaneous reduction of tau
acetylation at residue K280 using the acetylated tau-specific antibody ac-K280 (Fig 5B). There-
fore, MAP acetylation is negatively regulated by interactions with tubulin that engage posi-
tively charged MAP lysine residues.
To evaluate whether MAP acetylation can influence MT stability, MAPs were co-expressed
with either wild-type CBP or an enzymatically-inactive CBP-LD mutant (L1435A/D1436A)
that is incapable of acetylating MAP lysines (Fig 6). Active MAPs are known to stabilize MTs
leading to prominent MT bundling or cabling, as detected by tubulin immunoreactivity [23–
25]. While MT bundles still formed under all conditions tested, CBP-catalyzed acetylation of
tau, MAP2c, or MAP4 (Fig 6, panels a-b, e-f, i-j) resulted in less prominent and less elaborated
MT bundles compared to the baseline MAP activity observed with the inactive CBP-LD
mutant (Fig 6, panels c-d, g-h, k-l), as observed by immunofluorescence with an acetylated
tubulin antibody. Supporting this observation, further biochemical analysis by immunoblot-
ting showed a reduction in either MAP2 or MAP4-mediated MT stabilization when these
MAPs were acetylated in the presence of active CBP (Fig 6, panels m-o). Finally, we analyzed
Fig 5. MAP interactions with tubulin impair MAP acetylation A) Bovine brain derived MAP-rich fractions were incubated in the absence
or presence of increasing concentrations of tubulin (1–10 μM), and analyzed in auto-acetylation reactions containing [14C]-acetyl-CoA. B)
Reactions similar to (A) above were incubated with unlabeled acetyl-CoA in the presence of tubulin and analyzed by immunoblotting using
acetylated lysine (Acetyl-Lys), acetylated tau (Ac-K280), and total tau (T46) antibodies. We note that the addition of tubulin progressively
inhibited tau and MAP2 acetylation. Shown are representative gels and immunoblots from N = 3 independent experiments.
doi:10.1371/journal.pone.0168913.g005
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MAP2 in primary neurons differentiated from 4–22 days in vitro (DIV). Using a pan-acetyl-
lysine antibody, we observed an increase in acetylated MTs (~ 55 kDa), which correlated with
an apparent reduction of MAP2 acetylation-immunoreactive bands (~ 70 kDa) in mature neu-
rons from 11–22 DIV (S2 Fig). Taken together, these results support the notion that lysine
acetylation of MAPs within the MTBR can inhibit MAP-dependent MT stabilization.
Discussion
Here, we provide the first evidence for conserved lysine acetylation as a mechanism regulating
MAP2/Tau family members. Although acetylation has traditionally been viewed in the context
of histones and gene transcription, recent proteomics approaches have identified acetylated
targets in the cytoplasm and other organelles [15]. For example, the mitochondria harbors
>100 acetylated targets encompassing 20% of total mitochondrial proteins [26], highlighting
an emerging acetylation landscape. Several acetyltransferases (HATs) and deacetylases
(HDACs) are enriched in the cytoplasm and are firmly associated with MTs [16, 18], suggest-
ing that in addition to tubulin acetylation, cytosolic acetylated substrates may regulate cyto-
skeletal dynamics and coordinate cytoplasmic signaling events. Indeed, global proteomics
Fig 6. MAP acetylation alters MAP-mediated MT stabilization QBI-293 cells were transfected with 2N4R-tau (panels a-d), MAP2c (panels e-h),
or MAP4 (panels i-l) in the presence of wild-type CBP (top row) or an inactive CBP-LD mutant (bottom row). MT bundling in MAP-transfected cells
(green) was determined 48 hr later by acetylated tubulin immunofluorescence (red), an indicator of MAP-induced MT stabilization. Note, all MAPs
tested promoted baseline MT bundling in the absence of CBP activity (CBP-LD mutant), which was less elaborated upon MAP acetylation with
active wild-type CBP. Scale bar represents 50 μm. m-o) QBI-293 cells were transfected with MAP2c (m) or MAP4 (n) in the presence or absence of
wild-type CBP and analyzed by immunoblotting using the indicated antibodies. Shown are representative images and immunoblots from N = 3
independent experiments (immunoblots depict N = 3 technical replicates in the presence of CBP). Quantification of acetylated MTs by densitometry
analysis was determined (o). The double asterisk (**) indicates statistical significance with p-value = 0.005, as determined by student t-test.
doi:10.1371/journal.pone.0168913.g006
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analysis in cell culture and a variety of mouse tissues indicate prominent acetylation of cyto-
skeletal proteins including actin and microtubule-associated factors [15, 27, 28].
Our previous mass spectrometry analysis of either recombinant tau proteins or purified tau
isolated from cultured cells identified four major acetylation sites in cells (K163, K280, K281,
and K369) and several additional in vitro acetylation sites, most of which cluster within the tau
MTBR [3], an observation that was recently validated and extended in vivo using wild-type
mouse brain [7]. Since tau proteins have emerged as a dominant acetylated substrate, we inves-
tigated acetylation of the related MAP2 and MAP4 proteins, which contain sequence and
structural homology [13]. Using a cell-based MAP purification method, we identified a series
of acetylated MAP2 and MAP4 lysines, many of which cluster in the lysine-rich MTBR that
regulates MAP-MT binding.
We reveal at least two novel acetylation motifs that show a striking conservation among
MAP2 family members: [K-N-V-K/R-S-K] and [V-Q/K-I-X-X-X/K-K]. Consistent with
enhanced acetylation at lysine-rich motifs, recent studies indicate that lysine acetylation pref-
erentially occurs in a general lysine-rich local environment, in which neighboring lysines facil-
itate primary lysine acetylation [27, 29]. Secondly, the acetylated lysines identified in our study
often contain I/V residues at positions P+2 or P-2 (e.g. 332VQIVTKK/I339 in MAP2c) or D/E
residues at positions ranging from P-4 to P+4 (e.g. 363VKIESVK/LD371 in MAP2c) relative to
the primary acetylated lysine. In the latter scenario, such a configuration may act to enhance
local acetylation by lowering the pKa of the substrate lysine, which was recently suggested by
global acetylation mapping studies [27, 30].
It is currently unclear why MAPs are redundantly acetylated at the N-terminus of repeats
2–4 within the general [V-Q/K-I-X-X-X/K-K] consensus acetylation motif. High resolution
NMR analysis indicates that the beginning of the tau repeats represent strong binding sites for
microtubules [31, 32], suggesting acetylation could provide reversible regulatory control over
MAP-MT binding. While the number of repeats is important for MT stabilization (i.e. four
repeats bind MTs with higher affinity than three repeats), their order may not be critical [33].
In fact, using tau proteins, one can change the connection between flanking regions and
repeats, and one can even swap repeats without a major effect on tau-MT binding [33]. Thus,
MAP-MT interactions could be distributed independently and spread over the entire repeat
region, consistent with a weak MT binding model for tau [34]. Based on our results, it is plau-
sible that each repeat could be regulated independently, potentially via specific acetylation
events within the N-terminal [V-Q/K-I-X-X-X/K-K] motifs.
Tau residues K280 and K281 in the 2nd repeat, in particular, make an unusually large contri-
bution to MT-binding that is abrogated upon neutralization via lysine acetylation [3, 10]. Fur-
thermore, both K280 and K281 can undergo acetylation individually, or in tandem (i.e. doubly
acetylated), suggesting that any steric effects of individually acetylated lysines may not impair, but
rather might actually promote, subsequent acetylation locally within the repeats (TJC, unpub-
lished observations). Supporting the conservation of acetylation at tau K280/K281 in other
MAPs, the homologous double lysines in the 3rd repeat of MAP2c (332VQIVTKK338), the 2nd
repeat of MAP4 (992VQIVSKK998) and the 3rd repeat of MAP4 (1023VQIQNKK1029) are all tar-
geted by acetylation, either singly or doubly, in an analogous manner (Fig 2, Tables 1 and 2). Our
results support the notion of independent MT interactions among the individual repeats and are
consistent with double lysine-containing motifs, in particular, contributing to strong electrostatic
interactions with MTs, as originally proposed for tau [10, 33]. These are the same lysines that are
also subject to acetylation, likely providing regulation of MAP function and MT dynamics.
While we and others have shown that CBP catalyzes tau acetylation with high affinity in trans
[3, 5, 6, 21], CBP/p300 is not prominently localized to the neuronal cytoplasm where tau and
related MAPs are enriched [35]. Alternatively, evidence also indicates that MAP auto-acetylation
MAP2/Tau Family Members Undergo Lysine Acetylation
PLOS ONE | DOI:10.1371/journal.pone.0168913 December 21, 2016 13 / 17
can occur in the presence of acetyl-CoA alone (Fig 3) [21]. Although this phenomenon is not
fully characterized, many acetyltransferases control their own catalytic activity via positive feed-
back auto-acetylation [36–41]. We previously showed that tau can transfer acetyl groups onto its
own lysine residues [21], a mechanism that appears to be conserved among MAP2 family mem-
bers (Fig 4), which is consistent with the mechanism previously proposed for MYST and N-ary-
lamine (NAT)-family acetyltransferases [42, 43], to which MAPs have some limited sequence
homology [21]. A recent global proteomics study indicated that many acetylated substrates
undergo chemical auto-acetylation in the apparent absence of acetyltransferase activity [30], in
which case lysine specificity may be controlled instead by lysine accessibility, specific lysine pKa
values, and the presence of basic residues preceding the acetylated lysine. Thus, the lysine-rich
MTBRs, and in particular the double lysine-containing regions described here, may represent
conserved sites of auto-regulated chemical acetylation once MAPs have disengaged from MTs, a
PTM that would likely negatively regulate MAP-MT binding. Future studies to identify and
characterize putative MAP2 family acetyltransferase(s) could further shed light on the contribu-
tion of auto-regulated chemical acetylation vs. enzyme-catalyzed acetylation within the critical
MTBR domain.
In summary, we provide evidence for conservation of lysine acetylation among MAP2/Tau
family proteins. Future efforts to dissect how acetylation regulates MAP conformation or bind-
ing affinity could provide insight into MT dynamics, particularly during neuronal develop-
ment, neuronal plasticity, or under neurodegenerative conditions when MT regulation is
particularly dynamic and vulnerable. Lastly, our study could uncover site-specific MAP acety-
lation at particular lysine residues (or combinations thereof) as a critical factor in disease path-
ogenesis that may distinguish tau from its close relatives, which could factor into the selective
tau toxicity observed in AD and related tauopathies.
Supporting Information
S1 Fig. Mass spectrometry analysis confirmed MAP2c acetylation. QBI-293 cells treated
were transfected with MAP2c in the presence of CBP and MAP2c was immunoprecipitated
with an anti-MAP T46 antibody, separated by SDS-PAGE followed by gel excision and mass
spectrometry analysis. In the absence of CBP, no acetylation was detected. In the presence of
CBP, one of the major acetylated peptides identified was the doubly modified lysine containing
peptide, GGQVQIVTKKIDLSHVTSK (K337/K338), with significant ion scores and p-values
(see Table 1 for the full list of acetylation sites). The corresponding m/z spectrum is shown.
(TIF)
S2 Fig. Acetylated MAP2 analysis in primary neuronal cultures. Primary cortical neurons
were differentiated from 4–22 days in vitro (DIV). Neuronal lysates were harvested and ana-
lyzed by immunoblotting using pan-acetyl-lysine, MAP2, tubulin, and GAPDH antibodies.
Acetyl-lysine immunoreactive protein bands correlated with MAP2 migrating bands at ~ 70
kDa (top arrow), just above the prominent ~ 55 kDa acetyl-lysine immunoreactive band that
corresponds to acetylated tubulin (bottom arrow), which increased during neuronal differenti-
ation.
(TIF)
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